The Complete Semaglutide Dose Chart: Milligrams, Milliliters, and Insulin Syringe Units

Key Takeaways

• The standard semaglutide titration schedule for weight management is 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg weekly, with a 4-week interval between most steps.
• For diabetes (Ozempic indication), the schedule typically tops out at 2.0 mg weekly. STEP 1 (Wilding et al., NEJM 2021) used 2.4 mg.
• Compounded semaglutide is dosed by milliliters drawn into a U-100 insulin syringe. The unit count depends entirely on vial concentration.
• The most common compounded concentrations are 1 mg/mL, 2 mg/mL, 2.5 mg/mL, and 5 mg/mL. Each gives different unit readings for the same milligram dose.
• The chart below covers brand pen doses (Ozempic, Wegovy, Rybelsus) and compounded vial doses at every standard concentration.

Direct answer (40-60 words)

The standard semaglutide dose chart starts at 0.25 mg weekly, escalates to 0.5 mg at week 5, then 1.0 mg, 1.7 mg, and 2.4 mg with 4-week intervals between steps. For compounded semaglutide at 2.5 mg/mL, those doses correspond to 10, 20, 40, 68, and 96 units on a U-100 insulin syringe.

Table of contents

1. The 30-second answer
2. Why semaglutide is dosed in steps (titration)
3. Brand semaglutide dose chart: Ozempic, Wegovy, Rybelsus
4. Compounded semaglutide dose chart at every common concentration
5. The unit math: mg, mL, and U-100 syringe markings
6. How to find your vial's concentration
7. Step-by-step: drawing 0.5 mg accurately
8. Common dose chart mistakes and how to avoid them
9. Maintenance dose: when to stop titrating
10. FAQ
11. Sources
12. Footer disclaimers

Why semaglutide is dosed in steps (titration)

Semaglutide is titrated for one reason: side effects scale with dose, and a slow ramp lets the gut and brain adapt before the next bump. The published trial protocol (Wilding et al., NEJM 2021, STEP 1) found that titration over 16 weeks reduced nausea, vomiting, and diarrhea rates by roughly half compared with starting at the maintenance dose.

The schedule is not a clinical guess. It comes from dose-finding work in the SUSTAIN program (diabetes) and the STEP program (obesity). At each titration step, the body adjusts:

• GLP-1 receptors in the stomach desensitize partially, reducing nausea.
• The brain adapts to the new appetite signal.
• The gut microbiome shifts within 4 to 8 weeks.

If side effects are tolerable at week 4, you move up. If they are not, you stay at the current dose for an extra 2 to 4 weeks before trying again. Skipping a titration step is uncommon but acceptable in patients who tolerate the medication unusually well.

Brand semaglutide dose chart: Ozempic, Wegovy, Rybelsus

The three brand semaglutide products use different delivery devices and different maintenance doses.

Product	Indication	Delivery	Standard titration	Maintenance dose
Ozempic	Type 2 diabetes	Multi-dose pen, weekly subcutaneous injection	0.25 mg x 4 wk → 0.5 mg x 4 wk → 1.0 mg	1.0 mg or 2.0 mg weekly
Wegovy	Chronic weight management	Single-use pen, weekly subcutaneous injection	0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg, 4 weeks each	2.4 mg weekly
Rybelsus	Type 2 diabetes	Daily oral tablet	3 mg x 30 days → 7 mg x 30 days → 14 mg	14 mg daily

The three products contain the same molecule. Bioavailability differs because of the route. Oral semaglutide (Rybelsus) achieves about 1% bioavailability after passing through the gut and liver, which is why the milligram dose is so much higher than the injectable formulation.

For comparison purposes only, the molecule and indication footprint:

• Ozempic at 1.0 to 2.0 mg weekly: approved for type 2 diabetes, off-label use for weight loss is common.
• Wegovy at 2.4 mg weekly: approved for chronic weight management.
• Rybelsus at 14 mg daily: approved for type 2 diabetes, oral form.

The dose chart that follows focuses on the injectable forms, which are most relevant to weight management and to compounded prescriptions.

Compounded semaglutide dose chart at every common concentration

Compounded semaglutide is dispensed in a multi-dose vial. The patient draws a measured volume into a U-100 insulin syringe each week. The unit reading depends on the vial concentration, not on the milligram dose alone.

The four concentrations most commonly produced by U.S. compounding pharmacies:

Compounded semaglutide at 1 mg/mL

Dose	Volume	Units (U-100 syringe)
0.25 mg	0.25 mL	25 units
0.5 mg	0.50 mL	50 units
1.0 mg	1.00 mL	100 units
1.7 mg	1.70 mL	170 units
2.4 mg	2.40 mL	240 units

At 1 mg/mL, doses above 1.0 mg exceed the volume of a standard 1 mL U-100 syringe and require a larger barrel or two injections. This concentration is uncommon for that reason.

Compounded semaglutide at 2 mg/mL

Dose	Volume	Units (U-100 syringe)
0.25 mg	0.125 mL	12.5 units
0.5 mg	0.25 mL	25 units
1.0 mg	0.50 mL	50 units
1.7 mg	0.85 mL	85 units
2.4 mg	1.20 mL	120 units

A 2 mg/mL concentration requires a 1.5 mL or 3 mL U-100 syringe at the maintenance dose, which most patients do not have on hand. Reasonable for early titration steps only.

Compounded semaglutide at 2.5 mg/mL

Dose	Volume	Units (U-100 syringe)
0.25 mg	0.10 mL	10 units
0.5 mg	0.20 mL	20 units
1.0 mg	0.40 mL	40 units
1.7 mg	0.68 mL	68 units
2.4 mg	0.96 mL	96 units

This is the workhorse concentration. The 2.4 mg maintenance dose fits a 1 mL syringe, and the unit math is clean enough that titration is straightforward.

Compounded semaglutide at 5 mg/mL

Dose	Volume	Units (U-100 syringe)
0.25 mg	0.05 mL	5 units
0.5 mg	0.10 mL	10 units
1.0 mg	0.20 mL	20 units
1.7 mg	0.34 mL	34 units
2.4 mg	0.48 mL	48 units

The highest standard concentration. The full maintenance dose fits in 0.5 mL, which is fast and visible. Drawing the 0.25 mg starting dose is harder because 5 units on a U-100 syringe sits close to the bottom of the readable range. A 0.3 mL syringe with half-unit markings is recommended at this concentration.

For an in-depth treatment of unit conversion math at the boundaries of accuracy, see the tirzepatide unit conversion guide and the reconstitution guide.

The unit math: mg, mL, and U-100 syringe markings

A U-100 insulin syringe is calibrated for insulin, where 100 units equals 1 mL. The math is identical for any drug drawn into a U-100 syringe:

• 100 units = 1 mL
• 1 unit = 0.01 mL
• 50 units = 0.5 mL

To convert from a milligram dose to units on a U-100 syringe:

1. Divide the dose (mg) by the concentration (mg/mL) to get volume in mL.
2. Multiply mL by 100 to get units.

So at 2.5 mg/mL, a 1.0 mg dose is:

• 1.0 mg ÷ 2.5 mg/mL = 0.4 mL
• 0.4 mL x 100 = 40 units

At 5 mg/mL, the same 1.0 mg dose is:

• 1.0 mg ÷ 5 mg/mL = 0.2 mL
• 0.2 mL x 100 = 20 units

The same milligram dose can produce a 20, 40, or 50 unit reading on the syringe. Unit count alone is not a dose. Concentration matters every time.

How to find your vial's concentration

The concentration is on the vial label. Look for one of these formats:

• "Semaglutide Injection 2.5 mg/mL" is the cleanest format. Concentration is 2.5 mg per mL.
• "Semaglutide 5 mg / 2 mL Multi-Dose Vial" divides 5 by 2 to get 2.5 mg/mL.
• "Semaglutide for Reconstitution, 10 mg" is a powder. Concentration is set when you reconstitute. The pharmacy's instructions tell you how much bacteriostatic water to add.

If only total milligrams appear without volume, the concentration lives in the pharmacy's dispensing instructions. Two pharmacies dispensing "10 mg vials" can use 1 mL, 2 mL, or 4 mL of fill volume, producing 10, 5, or 2.5 mg/mL respectively. Same vial label, three different draw volumes for the same dose.

If you cannot find the concentration on the vial, the box, the paper insert, or the patient portal, call the pharmacy before drawing.

Step-by-step: drawing 0.5 mg accurately

The protocol below assumes a 2.5 mg/mL pre-mixed compounded semaglutide vial and a U-100 insulin syringe. Adjust the unit count using the chart above for other concentrations.

Materials:

• Compounded semaglutide vial
• U-100 insulin syringe with attached needle (0.3 mL or 0.5 mL barrel, 31-gauge, 5/16-inch)
• Two alcohol swabs
• Sharps container

Steps:

1. Wash hands with soap and water for 20 seconds.
2. Inspect the vial. Semaglutide should be clear and colorless to faintly straw-yellow. Cloudy, particulate, or unusually dark fluid is not safe to use. Call the pharmacy.
3. Wipe the vial top with an alcohol swab. Let it air-dry. Do not blow on it.
4. Pull back the plunger to draw 20 units of air into the syringe.
5. Insert the needle into the vial through the rubber stopper. Push the air in.
6. Invert the vial with the needle still inserted. Pull the plunger back to draw 20 units of liquid. Inspect for air bubbles. If bubbles are present, push the liquid back into the vial and re-draw, or flick the syringe sharply to dislodge bubbles, then push them back in.
7. Confirm 20 units in the syringe by holding it at eye level. The plunger's leading edge should sit on the 20-unit line.
8. Remove the needle from the vial. Do not recap.
9. Choose an injection site. Subcutaneous sites are the abdomen (avoid 2 inches around the navel), the front or outer thigh, or the back of the upper arm. Rotate sites weekly.
10. Wipe the injection site with the second alcohol swab. Let it air-dry.
11. Pinch a fold of skin. Insert the needle at 90 degrees (or 45 degrees if you have very little subcutaneous fat). Push the plunger steadily until empty.
12. Withdraw the needle. Apply gentle pressure with a clean tissue if there is any bleeding (rare).
13. Dispose of the syringe in a sharps container.

The whole process takes about 90 seconds once practiced.

Common dose chart mistakes and how to avoid them

Four recurring mistakes show up in FAERS reports and pharmacy adverse-event logs.

Mistake 1: Confusing milligrams with units.

"0.5 mg" and "50 units" can both apply at the 1 mg/mL concentration but produce different draws at every other concentration. Patients sometimes carry over a unit count from a previous concentration. The fix: write the unit count on the box in marker once, then refer to that number.

Mistake 2: Reading the wrong syringe size.

A 0.3 mL U-100 syringe has half-unit markings printed close together. Patients who first used a 1 mL syringe can miscount marks on the smaller barrel. Always confirm the printed numbers, not just the marks.

Mistake 3: Switching pharmacies without re-checking concentration.

Pharmacy A's 2.5 mg/mL switches to Pharmacy B's 5 mg/mL on a refill. The same 40-unit draw now delivers double the dose. Always read the concentration on every new vial.

Mistake 4: Drawing from a reconstituted vial without confirming the post-reconstitution concentration.

A 10 mg powder reconstituted with 2 mL of bacteriostatic water makes a 5 mg/mL solution. Reconstituted with 4 mL it is 2.5 mg/mL. Read the reconstitution instructions every time.

A 2024 study (Patel et al., Annals of Pharmacotherapy) found that 7.2% of patients self-administering compounded GLP-1s reported at least one suspected dosing error in the first 90 days. The four mistakes above accounted for the majority.

Maintenance dose: when to stop titrating

Most patients reach a maintenance dose by week 16 to 20 after starting semaglutide. The decision to stop titrating depends on three factors:

• Tolerability. If the current dose is tolerable and side effects are managed, the next step is reasonable. If side effects are unmanageable, stay or step down.
• Weight loss trajectory. STEP 1 patients who tolerated the full 2.4 mg dose lost about 14.9% of body weight at 68 weeks (Wilding et al., NEJM 2021). Patients on lower maintenance doses lose less, on a roughly proportional curve.
• Blood sugar response (for diabetes patients). A1c reduction at 1.0 mg vs 2.0 mg differs modestly (Davies et al., Diabetes Care 2023). Many patients reach target A1c at 1.0 mg.

There is no rule that you must reach 2.4 mg. Clinical practice ranges across the dose spectrum. Some patients hold at 1.0 mg or 1.7 mg long-term and see consistent results.

If you have reached your weight goal, the conversation shifts to maintenance dosing. Lower doses (0.5 to 1.0 mg) are sometimes used to maintain weight after the initial loss, though long-term data on de-escalation strategies is still evolving.

FAQ

What is the standard semaglutide dose chart for weight loss? The standard schedule is 0.25 mg weekly for 4 weeks, 0.5 mg for 4 weeks, 1.0 mg for 4 weeks, 1.7 mg for 4 weeks, then 2.4 mg as the maintenance dose. Total titration period is 16 weeks before reaching the full dose.

How is the semaglutide dose chart different for diabetes vs weight loss? Diabetes (Ozempic) typically tops out at 1.0 or 2.0 mg weekly. Weight management (Wegovy, or off-label use at higher doses) reaches 2.4 mg. The starting and titration doses are similar. The maintenance dose differs.

What unit count is 0.5 mg of semaglutide on a U-100 syringe? It depends on concentration. At 1 mg/mL it is 50 units. At 2.5 mg/mL it is 20 units. At 5 mg/mL it is 10 units. Always check your vial concentration.

How long does each titration step last? The standard interval is 4 weeks per step. If side effects are unmanageable, staying at the current dose for an extra 2 to 4 weeks before stepping up is acceptable. Skipping a step is uncommon and not generally recommended.

Can I split a weekly dose into two smaller injections? Semaglutide has a half-life of about 7 days, so weekly dosing matches the pharmacokinetic profile. Splitting into two doses 3 to 4 days apart is occasionally done if a patient needs a smoother side effect curve, but this should be a clinical decision, not self-managed.

What if I miss a dose? If less than 5 days have passed, take the missed dose as soon as you remember and resume the regular schedule. If more than 5 days have passed, skip the missed dose and take the next one on schedule. Do not double up.

Is the dose chart the same for compounded and brand semaglutide? The milligram dose is the same. The way you measure that dose differs: brand pens are pre-set, compounded vials require drawing the right volume into a U-100 syringe based on concentration.

Can I round up if my dose falls between unit markings? Small rounding (0.5 to 1 unit) usually has no clinical effect. Do not round up by more than 1 unit without provider input. Rounding down is generally safer if you are unsure.

Why does my 10 mg vial say 4 mL? That is the fill volume. 10 mg in 4 mL = 2.5 mg/mL concentration. The vial holds about 4 weeks of weekly maintenance doses at 1.0 mg, or roughly 16 weeks of starting doses at 0.25 mg.

What is the highest semaglutide dose currently approved? For chronic weight management, 2.4 mg weekly (Wegovy). For diabetes, 2.0 mg weekly (Ozempic 2 mg dose). Higher doses are not commonly used.

How do I know my pen is delivering the right dose? Brand pens are calibrated by the manufacturer. The dose dial advances by fixed click increments. For compounded vials, the dose depends on draw accuracy and concentration. A pen does the math for you. A vial does not.

Can I switch from compounded back to brand mid-titration? Yes, with provider guidance. Match the milligram dose, not the unit count. Switching at the maintenance dose is the cleanest transition point. Switching mid-titration is workable but requires careful matching.

Sources

1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
2. Davies MJ, et al. Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes. N Engl J Med. 2023;389:2152-2163.
3. Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). N Engl J Med. 2016;375:1834-1844.
4. Aroda VR, et al. PIONEER 1: Efficacy and Safety of Oral Semaglutide. Diabetes Care. 2019;42:1724-1732.
5. U.S. Food and Drug Administration. Wegovy (semaglutide) Prescribing Information. Updated 2024.
6. U.S. Food and Drug Administration. Ozempic (semaglutide) Prescribing Information. Updated 2024.
7. U.S. Food and Drug Administration. Rybelsus (semaglutide) Prescribing Information. Updated 2024.
8. U.S. Pharmacopeia, General Chapter on Insulin Injection Devices.
9. Patel N, et al. Self-administration accuracy of compounded GLP-1s. Ann Pharmacother. 2024;58(4):412-420.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.